![Patient flow diagram. BID, twice daily; PK, pharmacokinetics; QD, once... | Download Scientific Diagram Patient flow diagram. BID, twice daily; PK, pharmacokinetics; QD, once... | Download Scientific Diagram](https://www.researchgate.net/publication/325372028/figure/fig1/AS:630331015172096@1527294033000/Patient-flow-diagram-BID-twice-daily-PK-pharmacokinetics-QD-once-daily.png)
Patient flow diagram. BID, twice daily; PK, pharmacokinetics; QD, once... | Download Scientific Diagram
![Abbreviations: BID = twice daily; d = days; IV = intravenous; QID = 4... | Download Scientific Diagram Abbreviations: BID = twice daily; d = days; IV = intravenous; QID = 4... | Download Scientific Diagram](https://www.researchgate.net/publication/309744625/figure/fig2/AS:624439670616068@1525889427306/Abbreviations-BID-twice-daily-d-days-IV-intravenous-QID-4-times-per-day-SCFN.png)
Abbreviations: BID = twice daily; d = days; IV = intravenous; QID = 4... | Download Scientific Diagram
![Low-dose ticagrelor yields an antiplatelet efficacy similar to that of standard-dose ticagrelor in healthy subjects: an open-label randomized controlled trial | Scientific Reports Low-dose ticagrelor yields an antiplatelet efficacy similar to that of standard-dose ticagrelor in healthy subjects: an open-label randomized controlled trial | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fsrep31838/MediaObjects/41598_2016_Article_BFsrep31838_Fig1_HTML.jpg)
Low-dose ticagrelor yields an antiplatelet efficacy similar to that of standard-dose ticagrelor in healthy subjects: an open-label randomized controlled trial | Scientific Reports
![Once-daily dose of glaucoma drug omidenepag isopropyl offers similar benefit as two doses - American Academy of Ophthalmology Once-daily dose of glaucoma drug omidenepag isopropyl offers similar benefit as two doses - American Academy of Ophthalmology](https://d31g6oeq0bzej7.cloudfront.net/Assets/image/png/7a3e1fc6-d4ac-42bc-a9fc-47dfaf406ae2.png)
Once-daily dose of glaucoma drug omidenepag isopropyl offers similar benefit as two doses - American Academy of Ophthalmology
![Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours | British Journal of Cancer Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41416-021-01632-2/MediaObjects/41416_2021_1632_Fig1_HTML.png)